Chlorpromazine Hydrochloride Uses

How long did you take this medication to work?

What is Chlorpromazine Hydrochloride?

Chlorpromazine Hydrochloride is an anti-psychotic medication in a group of drugs called phenothiazines (FEEN-oh-THYE-a-zeens). It works by changing the actions of chemicals in your brain.

Chlorpromazine Hydrochloride is used to treat psychotic disorders such as schizophrenia or manic-depression, and severe behavioral problems in children ages 1 through 12.

Chlorpromazine Hydrochloride is also used to treat nausea and vomiting, anxiety before surgery, chronic hiccups, acute intermittent porphyria, and symptoms of tetanus.

Chlorpromazine Hydrochloride may also be used for purposes not listed in this medication guide.

Chlorpromazine Hydrochloride indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.


Intractable hiccup

Adult: Initially, 25-50 mg 3-4 times daily for 2-3 days; if unresponsive, may admin 25-50 mg via IM inj. If still necessary, 25-50 mg in 500-1000 ml of normal saline may be given via slow IV infusion.

Child: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.

Elderly: Initially, 1/3-½ the normal adult dose.



Adult: 25 mg tid; may be given as a single 75 mg dose at night.

Maintenance: 25-100 mg tid increased to ≥1 g daily as required in psychotic patients.

Child: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.

Elderly: Initially, 1/3-½ the normal adult dose.



Adult: 25-50 mg repeated every 6-8 hr. Substitute with oral therapy as soon as possible.

Child: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.

Elderly: Initially, 1/3-½ the normal adult dose.


Nausea and vomiting

Adult: Initially, 25 mg via IM inj, followed by 25-50 mg every 3-4 hr until vomiting stops.

Child: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.

Elderly: Initially, 1/3-½ the normal adult dose.



Adult: 100 mg every 6-8 hr as suppositories.

How should I use Chlorpromazine Hydrochloride?

Use Chlorpromazine Hydrochloride as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Chlorpromazine Hydrochloride.

Uses of Chlorpromazine Hydrochloride in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Use: Labeled Indications

Behavioral problems: Treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations).

Bipolar disorder: Treatment of manic episodes associated with bipolar disorder.

Hiccups: Treatment of intractable hiccups.

Hyperactivity: Short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressiveness, mood lability, and poor frustration tolerance.

Nausea/Vomiting: Management of nausea and vomiting.

Porphyria, acute intermittent: Treatment of acute intermittent porphyria.

Schizophrenia/Psychotic disorders: Treatment of schizophrenia and psychotic disorders.

Surgery: Management of restlessness and apprehension prior to surgery.

Tetanus: Adjunctive therapy in the treatment of tetanus.

Off Label Uses

Nausea and vomiting of pregnancy

Based on the American College of Obstetricians and Gynecologists (ACOG) Nausea and Vomiting in Pregnancy guidelines, the use of Chlorpromazine Hydrochloride may be considered for adjunctive treatment of nausea and vomiting in pregnant women. Use is reserved for women with dehydration when symptoms persist following preferred pharmacologic therapies.

Chlorpromazine Hydrochloride description


The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, Chlorpromazine Hydrochloride's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine Hydrochloride has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem]

Chlorpromazine Hydrochloride dosage

Chlorpromazine Hydrochloride Dosage

Applies to the following strength(s): 30 mg/mL; 100 mg/mL; 25 mg/mL; 30 mg; 75 mg; 150 mg; 25 mg; 100 mg; 10 mg/5 mL; 10 mg; 50 mg; 200 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Psychosis

IM: Initial Dose 25 to 50 mg. The dose may be repeated in one hour. Subsequent doses may be increased and given every 2 to 4 hours as needed.

Oral: Initial Dose: 10 to 25 mg orally 3 times a day. Total daily doses should be increased in 20 to 50 mg increments every 3 or 4 days until symptoms are controlled.

Usual Maintenance Dose: 200 mg/day orally

Some patients require higher dosages (e.g., 800 mg daily is not uncommon in discharged mental patients). Increase dosage gradually until symptoms are controlled. Maximum improvement may not be seen for weeks or even months. Continue optimum dosage for 2 weeks, then gradually reduce dosage to the lowest effective maintenance level.

Usual Adult Dose for Mania

Oral: 10 mg orally 3 to 4 times a day or 25 mg orally 2 to 3 times a day.

More severe cases: 25 mg orally 3 times a day.

After 1 to 2 days, dose may be increased by 20 to 50 mg/day at semiweekly intervals.

Prompt control of severe symptoms: 25 mg IM one time.

If necessary, repeat in 1 hour. Subsequent doses should be oral, 25 to 50 mg three times a day.

IM: 25 mg injection one time. If necessary, may give additional 25 to 50 mg injection in 1 hour.

Increase subsequent doses gradually over several days up to 400 mg every 4 to 6 hours in exceptionally severe cases.

Usually patient becomes quiet and cooperative within 24 to 48 hours and oral doses may be substituted.

Oral: 500 mg/day is generally sufficient. Gradual increases to 2000 mg/day or more may be necessary.

There is usually little therapeutic gain to be achieved by exceeding 1000 mg/day for extended periods.

Less acutely disturbed

Oral: 25 mg three times a day.

May increase gradually until effective dose is reached, usually 400 mg/day.

Usual Adult Dose for Nausea/Vomiting

Oral: 10 to 25 mg every 4 to 6 hours as needed. May increase, if necessary.

IM: 25 mg one time. If no hypotension occurs, give 25 to 50 mg every 3 to 4 hours as needed, then switch to oral dosage.

Rectal: One 100 mg suppository every 6 to 8 hours as needed. In some patients, half this dose will do.

Nausea/Vomiting During Surgery:

IM: 12.5 mg one time. May repeat in 30 minutes if necessary and if no hypotension occurs.

IV: 2 mg at 2 minute intervals. Do not exceed 25 mg. Dilute to 1 mg/mL.

Usual Adult Dose for Light Sedation

For light sedation prior to a medical or surgical procedure:

Oral: 25 to 50 mg, 2 to 3 hours before the operation.

IM: 12.5 to 25 mg, 1 to 2 hours before operation.

Usual Adult Dose for Hiccups

Oral: 25 to 50 mg 3 to 4 times a day.

IM: If symptoms persist for 2 to 3 days, give 25 to 50 mg IM.

IV infusion: Should symptoms persist, use slow IV infusion: 25 to 50 mg in 500 to 1000 mL of saline.

Usual Adult Dose for Porphyria

Oral: 25 to 50 mg 3 to 4 times a day.

Can usually be discontinued after several weeks, but maintenance therapy may be necessary for some patients.

IM: 25 mg injection 3 to 4 times a day until patient can take oral therapy.

Usual Adult Dose for Tetanus

IM: 25 to 50 mg given 3 to 4 times daily, usually in conjunction with barbiturates. Total doses and frequency of administration must be determined by the patient's response, starting with low doses and increasing gradually.

IV: 25 to 50 mg diluted to at least 1 mg/mL and administered at a rate of 1 mg/min.

Usual Pediatric Dose for Opiate Withdrawal

less than 1 month:

Neonatal abstinence syndrome (withdrawal from maternal opioid use; controls CNS and gastrointestinal symptoms):

Intramuscular: Initial: 0.55 mg/kg/dose given every 6 hours; change to oral after approximately 4 days, decrease dose gradually over 2 to 3 weeks. Note: Chlorpromazine Hydrochloride is rarely used for neonatal abstinence syndrome due to adverse effects such as hypothermia, cerebellar dysfunction, decreased seizure threshold, and eosinophilia; other agents are preferred.

Usual Pediatric Dose for Schizophrenia

6 months and older:

Oral: 0.5 to 1 mg/kg/dose orally every 4 to 6 hours; older children may require 200 mg/day or higher

intramuscular or intravenous: 0.5 to 1 mg/kg/dose every 6 to 8 hours

Maximum recommended doses:

less than 5 years (less than 22.7 kg): 40 mg/day

5 years and older: (22.7 to 45.5 kg): 75 mg/day

Usual Pediatric Dose for Nausea/Vomiting

Nausea and vomiting:

Oral: 0.5 to 1 mg/kg/dose every 4 to 6 hours as needed

intramuscular or intravenous: 0.5 to 1 mg/kg/dose every 6 to 8 hours;

Maximum recommended doses:

less than 5 years (less than 22.7 kg): 40 mg/day

5 and older (22.7-45.5 kg): 75 mg/day

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Adjust dosage to individual and the severity of condition, recognizing that the mg for mg potency relationship among all dosage forms has not been precisely established clinically. It is important to increase dosage until symptoms are controlled. Dosage should be increased more gradually in debilitated or emaciated patients. In continued therapy, gradually reduce dosage to the lowest effective maintenance level, after symptoms have been controlled for a reasonable period.

In general, dosage recommendations for other oral forms of the drug may be applied to the sustained release capsules on the basis of total daily dosage in milligrams.

The 100 mg and 200 mg tablets are for use in severe neuropsychiatric conditions.


In general, dosage levels should be lower in the elderly, the emaciated and the debilitated. Chlorpromazine Hydrochloride should be used cautiously in patients with cardiovascular, liver or renal disease.


Data not available

Other Comments

Chlorpromazine Hydrochloride should generally not be used in children under 6 months of age except where potentially lifesaving.

More about Chlorpromazine Hydrochloride

Consumer resources

Professional resources

Related treatment guides

Chlorpromazine Hydrochloride interactions

See also:
What other drugs will affect Chlorpromazine Hydrochloride?


Potentiation of anticholinergic effects of antiparkinson agents and TCAs may lead to an anticholinergic crisis. Additive orthostatic hypotensive effect in combination with MAOIs. Reverses antihypertensive effect of guanethidine, methyldopa and clonidine.

Potentially Fatal: Additive depressant effect with sedatives, hypnotics, antihistamines, general anaesthetics, opiates and alcohol.

Chlorpromazine Hydrochloride side effects

See also:
What are the possible side effects of Chlorpromazine Hydrochloride?

Note: Some adverse effects of Chlorpromazine Hydrochloride may be more likely to occur, or occur with greater intensity, in patients with special medical problems, e.g., patients with mitral insufficiency or pheochromocytoma have experienced severe hypotension following recommended doses.

Drowsiness, usually mild to moderate, may occur, particularly during the first or second week, after which it generally disappears. If troublesome, dosage may be lowered.


Overall incidence has been low, regardless of indication or dosage. Most investigators conclude it is a sensitivity reaction. Most cases occur between the second and fourth weeks of therapy. The clinical picture resembles infectious hepatitis, with laboratory features of obstructive jaundice, rather than those of parenchymal damage. It is usually promptly reversible on withdrawal of the medication; however, chronic jaundice has been reported.

There is no conclusive evidence that preexisting liver disease makes patients more susceptible to jaundice. Alcoholics with cirrhosis have been successfully treated with Chlorpromazine Hydrochloride without complications. Nevertheless, the medication should be used cautiously in patients with liver disease. Patients who have experienced jaundice with a phenothiazine should not, if possible, be reexposed to Chlorpromazine Hydrochloride or other phenothiazines.

If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

Liver function tests in jaundice induced by the drug may mimic extrahepatic obstruction; withhold exploratory laparotomy until extrahepatic obstruction is confirmed.

Hematological Disorders, including agranulocytosis, eosinophilia, leukopenia, hemolytic anemia, aplastic anemia, thrombocytopenic purpura and pancytopenia have been reported.


Warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Most cases have occurred between the 4th and 10th weeks of therapy; patients should be watched closely during that period.

Moderate suppression of white blood cells is not an indication for stopping treatment unless accompanied by the symptoms described above.



Postural hypotension, simple tachycardia, momentary fainting and dizziness may occur after the first injection; occasionally after subsequent injections; rarely, after the first oral dose. Usually recovery is spontaneous and symptoms disappear within 1/2 to 2 hours. Occasionally, these effects may be more severe and prolonged, producing a shock-like condition.

To minimize hypotension after injection, keep patient lying down and observe for at least 1/2 hour. To control hypotension, place patient in head-low position with legs raised. If a vasoconstrictor is required, norepinephrine and phenylephrine are the most suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.


Particularly nonspecific, usually reversible Q and T wave distortions–have been observed in some patients receiving phenothiazine tranquilizers, including Chlorpromazine Hydrochloride.

Note: Sudden death, apparently due to cardiac arrest, has been reported.

CNS Reactions


Neuromuscular reactions include dystonia, motor restlessness, pseudo-parkinsonism and tardive dyskinesia, and appear to be dose-related. They are discussed in the following paragraphs:


Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Motor Restlessness

Symptoms may include agitation or jitteriness and sometimes insomnia. These symptoms often disappear spontaneously. At times these symptoms may be similar to the original neurotic or psychotic symptoms. Dosage should not be increased until these side effects have subsided.

If these symptoms become too troublesome, they can usually be controlled by a reduction of dosage or change of drug. Treatment with anti-parkinsonian agents, benzodiazepines or propranolol may be helpful.


Symptoms may include: mask-like facies, drooling, tremors, pillrolling motion, cogwheel rigidity and shuffling gait. In most cases, these symptoms are readily controlled when an anti-parkinsonism agent is administered concomitantly. Anti-parkinsonism agents should be used only when required. Generally, therapy of a few weeks to 2 or 3 months will suffice. After this time, patients should be evaluated to determine their need for continued treatment. (Note: Levodopa has not been found effective in antipsychotic-induced pseudo-parkinsonism.) Occasionally it is necessary to lower the dosage of Chlorpromazine Hydrochloride or to discontinue the drug.

Tardive Dyskinesia

As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. The syndrome can also develop, although much less frequently, after relatively brief treatment periods at low doses. This syndrome appears in all age groups. Although its prevalence appears to be highest among elderly patients, especially elderly women, it is impossible to rely upon prevalence estimates to predict at the inception of antipsychotic treatment which patients are likely to develop the syndrome. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities. In rare instances, these involuntary movements of the extremities are the only manifestations of tardive dyskinesia. A variant of tardive dyskinesia, tardive dystonia, has also been described.

There is no known effective treatment for tardive dyskinesia; anti-parkinsonism agents do not alleviate the symptoms of this syndrome. If clinically feasible, it is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. It has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time the syndrome may not develop.


Psychotic symptoms and catatonic-like states have been reported rarely.


Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs.

Cerebral edema has been reported.

Convulsive seizures (petit mal and grand mal) have been reported, particularly in patients with EEG abnormalities or history of such disorders.

Abnormality of the cerebrospinal fluid proteins has also been reported.

Allergic Reactions of a mild urticarial type or photosensitivity are seen. Avoid undue exposure to sun. More severe reactions, including exfoliative dermatitis, have been reported occasionally.

Contact dermatitis has been reported in nursing personnel; accordingly, the use of rubber gloves when administering Chlorpromazine Hydrochloride injectable is recommended.

In addition, asthma, laryngeal edema, angioneurotic edema and anaphylactoid reactions have been reported.

Endocrine Disorders

Lactation and moderate breast engorgement may occur in females on large doses. If persistent, lower dosage or withdraw drug. False-positive pregnancy tests have been reported, but are less likely to occur when a serum test is used. Amenorrhea and gynecomastia have also been reported. Hyperglycemia, hypoglycemia and glycosuria have been reported.

Autonomic Reactions

Occasional dry mouth; nasal congestion; nausea; obstipation; constipation; adynamic ileus; urinary retention; priapism; miosis and mydriasis; atonic colon; ejaculatory disorders/impotence.

Special Considerations in Long-Term Therapy

Skin pigmentation and ocular changes have occurred in some patients taking substantial doses of Chlorpromazine Hydrochloride for prolonged periods.


Rare instances of skin pigmentation have been observed in hospitalized mental patients, primarily females who have received the drug usually for 3 years or more in dosages ranging from 500 mg to 1500 mg daily. The pigmentary changes, restricted to exposed areas of the body, range from an almost imperceptible darkening of the skin to a slate gray color, sometimes with a violet hue. Histological examination reveals a pigment, chiefly in the dermis, which is probably a melanin-like complex. The pigmentation may fade following discontinuance of the drug.


Ocular changes have occurred more frequently than skin pigmentation and have been observed both in pigmented and nonpigmented patients receiving Chlorpromazine Hydrochloride usually for 2 years or more in dosages of 300 mg daily and higher. Eye changes are characterized by deposition of fine particulate matter in the lens and cornea. In more advanced cases, star-shaped opacities have also been observed in the anterior portion of the lens. The nature of the eye deposits has not yet been determined. A small number of patients with more severe ocular changes have had some visual impairment. In addition to these corneal and lenticular changes, epithelial keratopathy and pigmentary retinopathy have been reported. Reports suggest that the eye lesions may regress after withdrawal of the drug. Since the occurrence of eye changes seems to be related to the dosage levels and/or duration of therapy, it is suggested that long-term patients on moderate to high dosage levels have periodic ocular examinations.


The etiology of both of these reactions is not clear, but exposure to light, along with dosage/duration of therapy, appears to be the most significant factor. If either of these reactions is observed, the physician should weigh the benefits of continued therapy against the possible risks and, on the merits of the individual case, determine whether or not to continue present therapy, lower the dosage, or withdraw the drug.

Other Adverse Reactions

Mild fever may occur after large IM doses. Hyperpyrexia has been reported. Increases in appetite and weight sometimes occur. Peripheral edema and a systemic lupus erythematosus-like syndrome have been reported.

Note: There have been occasional reports of sudden death in patients receiving phenothiazines. In some cases, the cause appeared to be cardiac arrest or asphyxia due to failure of the cough reflex.

Chlorpromazine Hydrochloride contraindications

See also:
What is the most important information I should know about Chlorpromazine Hydrochloride?

Do not use in patients with known hypersensitivity to phenothiazines.

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.).

Active ingredient matches for Chlorpromazine Hydrochloride:

Chlorpromazine Hydrochloride

Unit description / dosage (Manufacturer)Price, USD
1 milliliter in 1 ampule
2 milliliter in 1 ampule
Chlorpromazine Hydrochloride injection 25 mg/mL (West Ward Pharmaceutical Corp. (US))
Chlorpromazine Hydrochloride tablet, sugar coated 100 mg/1 (Cardinal Health (US))
Chlorpromazine Hydrochloride tablet, sugar coated 50 mg/1 (REMEDYREPACK INC. (US))
Chlorpromazine Hydrochloride tablet, sugar coated 25 mg/1 (Mylan Institutional Inc. (US))
Chlorpromazine Hydrochloride tablet, sugar coated 200 mg/1 (Clinical Solutions Wholesale (US))
Chlorpromazine Hydrochloride tablet, sugar coated 10 mg/1 (Upsher Smith Laboratories, Inc. (US))
Chlorpromazine Hydrochloride tablet, film coated 25 mg/1 (Physicians Total Care, Inc. (US))
Chlorpromazine Hydrochloride tablet 200 mg/1 (REMEDYREPACK INC. (US))
Chlorpromazine Hydrochloride tablet 50 mg/1 (REMEDYREPACK INC. (US))

List of Chlorpromazine Hydrochloride substitutes (brand and generic names):

Chlorpromazine 25 mg/ml amp (Sun Pharmaceutical Industries)$ 8.04
ChlorproMAZINE HCl 200 mg tablet (Sun Pharmaceutical Industries)$ 1.19
Chlorpromazine 200 mg tablet (Sun Pharmaceutical Industries)$ 1.05
ChlorproMAZINE HCl 100 mg tablet (Sun Pharmaceutical Industries)$ 0.84
ChlorproMAZINE HCl 50 mg tablet (Sun Pharmaceutical Industries)$ 0.73
ChlorproMAZINE HCl 25 mg tablet (Sun Pharmaceutical Industries)$ 0.55
Chlorpromazine 100 mg tablet (Sun Pharmaceutical Industries)$ 0.39
ChlorproMAZINE HCl 10 mg tablet (Sun Pharmaceutical Industries)$ 0.37
Chlorpromazine 10 mg tablet (Sun Pharmaceutical Industries)$ 0.32
Chlorpromazine 50 mg tablet (Sun Pharmaceutical Industries)$ 0.30
Chlorpromazine 25 mg tablet (Sun Pharmaceutical Industries)$ 0.17
CHLORPROMAZINE Capsule/ Tablet / 50mg / 10 units (Sun Pharmaceutical Industries)$ 0.06
CHLORPROMAZINE Capsule/ Tablet / 25mg / 10 units (Sun Pharmaceutical Industries)$ 0.03
CHLORPROMAZINE Capsule/ Tablet / 100mg / 10 units (Sun Pharmaceutical Industries)$ 0.12
CHLORPROMAZINE Capsule/ Tablet / 200mg / 10 units (Sun Pharmaceutical Industries)$ 0.14
Chlorpromazine 10mg TAB / 10 (Sun Pharmaceutical Industries)$ 0.06
Chlorpromazine 25mg TAB / 12 (Sun Pharmaceutical Industries)$ 0.11
Chlorpromazine 50mg TAB / 12 (Sun Pharmaceutical Industries)$ 0.16
Chlorpromazine 100mg TAB / 12 (Sun Pharmaceutical Industries)$ 0.22
Chlorpromazine 2.5% INJ / 10x2ml (Sun Pharmaceutical Industries)$ 0.34
Chlorpromazine / Pfoshen 100 mg x 1000's (Sun Pharmaceutical Industries)
10 mg x 10's (Sun Pharmaceutical Industries)$ 0.06
25 mg x 12's (Sun Pharmaceutical Industries)$ 0.11
50 mg x 12's (Sun Pharmaceutical Industries)$ 0.16
100 mg x 12's (Sun Pharmaceutical Industries)$ 0.22
2.5 % x 2mlx10 (Sun Pharmaceutical Industries)$ 0.34
Chlorpromazine 50 mg Abbott Injection (Sun Pharmaceutical Industries)$ 0.02
CHLORPROMAZINE / AHPL tab 10 mg x 10's (Sun Pharmaceutical Industries)$ 0.06
CHLORPROMAZINE / AHPL tab 25 mg x 12's (Sun Pharmaceutical Industries)$ 0.11
CHLORPROMAZINE / AHPL tab 50 mg x 12's (Sun Pharmaceutical Industries)$ 0.16
CHLORPROMAZINE / AHPL tab 100 mg x 12's (Sun Pharmaceutical Industries)$ 0.22
CHLORPROMAZINE / AHPL inj 2.5 % x 2ml (Sun Pharmaceutical Industries)$ 0.34
CHLORPROMAZINE / SUN tab 25 mg x 10's (Sun Pharmaceutical Industries)$ 0.03
CHLORPROMAZINE / SUN tab 50 mg x 10's (Sun Pharmaceutical Industries)$ 0.06
CHLORPROMAZINE / SUN tab 100 mg x 10's (Sun Pharmaceutical Industries)$ 0.12
CHLORPROMAZINE / SUN tab 200 mg x 10's (Sun Pharmaceutical Industries)$ 0.14
Chlorpromazine tablet, film coated 25 mg/1 (Sun Pharmaceutical Industries)
Chlorpromazine tablet, film coated 50 mg/1 (Sun Pharmaceutical Industries)
Chlorpromazine tablet, film coated 100 mg/1 (Sun Pharmaceutical Industries)
Chlorpromazine 50mg Tablet (Sun Pharmaceutical Industries)$ 0.01


  1. DailyMed. "CHLORPROMAZINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". (accessed September 17, 2018).
  2. PubChem. "chlorpromazine". (accessed September 17, 2018).
  3. DrugBank. "chlorpromazine". (accessed September 17, 2018).


The results of a survey conducted on for Chlorpromazine Hydrochloride are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Chlorpromazine Hydrochloride. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet

Consumer reported price estimates

No survey data has been collected yet

Consumer reported time for results

No survey data has been collected yet

Consumer reported age

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 3 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 All Rights Reserved